Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3.

Pianko, S; Zeuzem, S; Chuang, Wl; Foster, Gr; Sarin, Sk; Flisiak, R; Lee, Cm; Andreone, P; Piratvisuth, T; Shah, S; Sood, A; George, J; Gould, M; Komolmit, P; Thongsawat, S; Tanwandee, T; Rasenack, J; Li, Y; Pang, M; Yin, Y; Feutren, G; Jacobson, Im